LONG BEACH, CALIF. — Today, much of the research around 3D bioprinting tissue and organs revolves around laying down enough cells in an abiotic substrate outside a living body, so they can culture and then be implanted where needed.

One company, however, believes a better method will be to print the cells inside of a human host, and take advantage of the body’s natural ability to incubate and promote cell reproduction. This method is called in-vivo.

William Warren, vice president of vaccine manufacturer Sanofi Pasteur’s VaxDesign Campus, explained to attendees of the RAPID 3D Printing Conference here this week that in-vivo bioprinting is also the least invasive procedure.

To read this article in full or to leave a comment, please click here